Skip to main content
SpringerLink
Log in
Book cover

Pediatric Obesity pp 369–376Cite as

Obesity and Metabolic Dysfunction in the Child with a Major Behavioral Disorder: Atypical Antipsychotics

  • Chapter
  • First Online:

  • 1702 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Obesity in childhood increases the risks of adult obesity and predisposes to metabolic complications including glucose intolerance, type 2 diabetes mellitus, hypertension, dyslipidemia, and the development of cardiovascular disease (1–4). Obesity also impacts physical appearance and may have profound psychosocial consequences including low self-esteem, lack of self-confidence, and social alienation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sjoberg RL, Nilsson KW, Leppert J. Obesity, shame, and depression in school-aged children: a population-based study. Pediatrics. Sept 2005;116(3):e389–92.

    Article  PubMed  Google Scholar 

  2. Vila G, Zipper E, Dabbas M, et al. Mental disorders in obese children and adolescents. Psychosom Med. May–Jun 2004;66(3):387–94.

    Article  PubMed  Google Scholar 

  3. Janssen I, Craig WM, Boyce WF, Pickett W. Associations between overweight and obesity with bullying behaviors in school-aged children. Pediatrics. May 2004;113(5):1187–94.

    Article  PubMed  Google Scholar 

  4. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. Nov 1999;156(11):1686–96.

    PubMed  CAS  Google Scholar 

  5. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. Apr 2003;54(4):565–7.

    Article  PubMed  Google Scholar 

  6. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60(Suppl 21):25–30.

    PubMed  Google Scholar 

  7. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. Dec 2002;63(12):1121–28.

    Article  PubMed  Google Scholar 

  8. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(Suppl 2):41–4.

    PubMed  CAS  Google Scholar 

  9. Cooper WO, Arbogast PG, Ding H. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6:79–83.

    Article  PubMed  Google Scholar 

  10. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry. Feb 2002;41(2):140–7.

    Article  PubMed  Google Scholar 

  11. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry. Jan 1996;57(1):29–31.

    PubMed  CAS  Google Scholar 

  12. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol. 1999;9(2):115–23.

    Article  PubMed  CAS  Google Scholar 

  13. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry. May 1997;36(5):694–700.

    Article  PubMed  CAS  Google Scholar 

  14. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. Jan 2003;28(Suppl 1):9–26.

    Article  PubMed  CAS  Google Scholar 

  15. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol. Winter 2002;12(4):337–45.

    Article  PubMed  Google Scholar 

  16. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. Winter 2001;11(4):415–24.

    Article  PubMed  CAS  Google Scholar 

  17. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. Jul 2006;45(7):771–91.

    Article  PubMed  Google Scholar 

  18. Starrenburg FC, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. Apr 2009;24(3):164–70.

    Article  PubMed  CAS  Google Scholar 

  19. Beasley CM Jr., Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. May 1997;7(2):125–37.

    Article  PubMed  CAS  Google Scholar 

  20. Beasley CM Jr., Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58(Suppl 10):13–7.

    PubMed  CAS  Google Scholar 

  21. Baptista T, Beaulieu S. Body weight gain, insulin, and leptin in olanzapine-treated patients. J Clin Psychiatry. Nov 2001;62(11):902–4.

    Article  PubMed  CAS  Google Scholar 

  22. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767–70.

    Article  PubMed  CAS  Google Scholar 

  23. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60(6):358–63.

    Article  PubMed  CAS  Google Scholar 

  24. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a 5-year naturalistic study. Am J Psychiatry. 2000;157:975–81.

    Article  PubMed  CAS  Google Scholar 

  25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 22 Sept 2005;353(12):1209–23.

    Article  PubMed  CAS  Google Scholar 

  26. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. Mar 2002;14(1):59–64.

    PubMed  Google Scholar 

  27. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. Jan 2007;89(1–3):91–100.

    Article  PubMed  Google Scholar 

  28. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. Jan 2006;15(1):177–206.

    Article  PubMed  Google Scholar 

  29. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. Jan 2004;29(1):133–45.

    Article  PubMed  CAS  Google Scholar 

  30. Correll C, Parikh U, Mugahl T, Olshanskiy V, Moroff M, Pleak R. Body composition changes associated with second-generation antipsychotics. Biol Psychiatry. 2005;57:36.

    Google Scholar 

  31. Saito E, Kafantaris V. Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol. Fall 2002;12(3):231–6.

    Article  PubMed  Google Scholar 

  32. Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol. Spring 2003;13(1):97–102.

    Article  PubMed  Google Scholar 

  33. McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. Oct 2008;162(10):929–35.

    Article  PubMed  Google Scholar 

  34. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 1 Jan 2004;66(1):51–7.

    Article  PubMed  Google Scholar 

  35. O’Brien SH, Holubkov R, Reis EC. Identification, evaluation, and management of obesity in an academic primary care center. Pediatrics. Aug 2004;114(2):e154–9.

    Article  PubMed  Google Scholar 

  36. Braet C, Tanghe A, Decaluwe V, Moens E, Rosseel Y. Inpatient treatment for children with obesity: weight loss, psychological well-being, and eating behavior. J Pediatr Psychol. Oct 2004;29(7):519–29.

    Article  PubMed  Google Scholar 

  37. Carrell A, Clark R, Peterson S, Nemeth B, Sullivan J, Allen D. Improvement of fitness, body composition, and insulin sensitivity in overweight children in a school-based exercise program. Arch Pediatr Adolesc Med. 2005;259:963–8.

    Article  Google Scholar 

  38. Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res. Nov 2001;9(Suppl 4):295S–301S.

    Article  PubMed  Google Scholar 

  39. Durant N, Cox J. Current treatment approaches to overweight in adolescents. Curr Opin Pediatr. Aug 2005;17(4):454–9.

    Article  PubMed  Google Scholar 

  40. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy. Jun 2009;29(6):725–35.

    Article  PubMed  CAS  Google Scholar 

  41. Molnar D. New drug policy in childhood obesity. Int J Obes (Lond). Sept 2005;29(Suppl 2):S62–5.

    Article  Google Scholar 

  42. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625–56.

    Article  PubMed  CAS  Google Scholar 

  43. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 15 Jun 2005;293(23):2873–83.

    Article  PubMed  CAS  Google Scholar 

  44. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. Nov 2002;35(6):205–19.

    Article  PubMed  CAS  Google Scholar 

  45. Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother. Mar 2004;5(3):633–42.

    Article  PubMed  CAS  Google Scholar 

  46. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. Mar 2005;90(3):1460–5.

    Article  PubMed  CAS  Google Scholar 

  47. Webb E, Viner R. Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped? Arch Dis Child. Sept 2006;91(9):793–4.

    Google Scholar 

  48. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. Jan 2002;25(1):89–94.

    Article  PubMed  CAS  Google Scholar 

  49. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. Apr 2002;159(4):655–7.

    Article  PubMed  Google Scholar 

  50. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. Dec 2006;163(12):2072–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rush University Medical Center, Chicago, IL, 60612, USA

    Lauren Shin

  2. Clinical Instructor of Psychiatry, Scott Nolan Center, Maryville Academy, Des Plaines, IL, 60016, USA

    Lauren Shin

  3. Freedom Trail Clinic, Harvard Medical School, Massachusetts General Hospital, Boston, MA, 02114, USA

    David C. Henderson

Authors
  1. Lauren Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David C. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatric Endocrinology, and Diabetes, Duke University, DUMC 3080, Durham, 27710, North Carolina, USA

    Michael Freemark

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shin, L., Henderson, D.C. (2010). Obesity and Metabolic Dysfunction in the Child with a Major Behavioral Disorder: Atypical Antipsychotics. In: Freemark, M. (eds) Pediatric Obesity. Contemporary Endocrinology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-60327-874-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-874-4_25

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-60327-873-7

  • Online ISBN: 978-1-60327-874-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation